Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 8
- Registration Number
- NCT03328104
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 102
- Registration Number
- NCT03321890
- Locations
- 🇨🇳
Department of Medical Oncology,Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- Yang Zhijun
- Target Recruit Count
- 60
- Registration Number
- NCT03298074
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT03220022
- Locations
- 🇺🇸
University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 650
- Registration Number
- NCT03206671
- Locations
- 🇫🇮
Turku University Hospital, Paediatric and Adolescent Haematology and Oncology, Turku, Finland
🇨🇭Universitäts-Kinderspital, Pädiatrische Onkologie, Zürich, Switzerland
🇨🇭Kinderspital Pädiatrische Hämatologie/ Onkologie, Luzern, Switzerland
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- Drug: AzacitidineDrug: DecitabineDrug: CytarabineDrug: DaunorubicinDrug: EtoposideCombination Product: ITMHADrug: IdarubicinDrug: FludarabineDrug: MitoxantroneDrug: SorafenibDrug: Erwinia asparaginaseDrug: G-CSFDrug: DexrazoxaneDrug: Asparaginase Erwinia Chrysanthemi, Recombinant-RywnBiological: Stem Cell Transplant
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT03164057
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸Children's Hospital of Central California, Madera, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 21
- Registration Number
- NCT03161054
- Locations
- 🇮🇹
A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
🇮🇹Ospedale di Castelfranco Veneto - Ematologia, Castelfranco Veneto, Italy
🇮🇹Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS c/o CORE (II piano) - Ematologia, Reggio Emilia, Italy
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 61
- Registration Number
- NCT03141359
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- Conditions
- Recurrent Acute Lymphoblastic LeukemiaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Adult Lymphoblastic LymphomaRecurrent Burkitt LeukemiaRecurrent Burkitt LymphomaRecurrent Childhood Lymphoblastic LymphomaRefractory Burkitt LeukemiaRefractory Lymphoblastic LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Burkitt Lymphoma
- Interventions
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT03136146
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients with Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT03132532
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.